Patient info Open main menu

AMBRISENTAN MYLAN 5 MG FILM-COATED TABLETS - patient leaflet, side effects, dosage

Contains active substance :

Dostupné balení:

Patient leaflet - AMBRISENTAN MYLAN 5 MG FILM-COATED TABLETS

Ambrisentan Mylan

Ambrisentan Mylan


10 mg


film-coated tablets

ambrisentan

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
  • – Keep this leaflet. You may need to read it again.

  • – If you have any further questions, ask your doctor, pharmacist or nurse.

  • – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

  • – If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
  • I.What Ambrisentan Mylan is and what it is used for

  • 2.What you need to know before you take Ambrisentan Mylan

  • 3. How to take Ambrisentan Mylan

1. what ambrisentan mylan is and what it is used for

Ambrisentan Mylan contains the active substance ambrisentan. It belongs to a group of medicines called other antihypertensives (used to treat high blood pressure).

It is used to treat pulmonary arterial hypertension (PAH) in adults. PAH is high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. In people with PAH, these arteries get narrower, so the heart has to work harder to pump blood through them. This causes people to feel tired, dizzy and short of breath.

Ambrisentan Mylan widens the pulmonary arteries, making it easier for the heart to pump blood through them.

This lowers the blood pressure and relieves the symptoms.

Ambrisentan Mylan may also be used in combination with other medicines used to treat PAH.

2. what you need to know before you take ambrisentan mylan

Do not take Ambrisentan Mylan:
  • – if you are allergic to ambrisentan or any of the other ingredients of this medicine (listed in section 6).

  • - if you are pregnant, if you are planning to become pregnant, or if you could become pregnant because you are not using reliable birth control (contraception). Please read the information under ‘Pregnancy’

  • – if you are breast feeding. Read the information under ‘Breast-feeding’

  • – if you have liver disease. Talk to your doctor, who will decide whether this medicine is suitable for you

  • – if you have scarring of the lungs, of unknown cause (idiopathic pulmonary fibrosis).

Warnings and precautions

  • Talk to your doctor, pharmacist or nurse before taking this medicine if you have: liver problems
  • anaemia (a reduced number of red blood cells)
  • swelling in the hands, ankles or feet caused by fluid (peripheral oedema)
  • lung disease where the veins in the lungs are blocked (pulmonary veno-occlusive disease).
Your doctor will decide whether

Ambrisentan Mylan is suitable for you.

You will need regular blood tests

Before you start taking Ambrisentan Mylan, and at regular intervals while you’re taking it, your doctor will take blood tests to check:

  • whether you have anaemia
  • whether your liver is working properly.

^ It is important that you have these regular blood tests for as long as you are taking Ambrisentan Mylan.

Signs that your liver may not be working properly include:

  • loss of appetite
  • feeling sick (nausea)
  • being sick (vomiting)
  • high temperature (fever)
  • pain in your stomach (abdomen)
  • yellowing of your skin or the whites of your eyes (jaundice)
  • dark-coloured urine
  • itching of your skin.

If you notice any of these signs:

^ Tell your doctor immediately.

Children and adolescents

Ambrisentan Mylan is not recommended for children and adolescents aged under

  • 4. Possible side effects

  • 5. How to store Ambrisentan Mylan

  • 6. Contents of the pack and other information

  • 18 years as the safety and effectiveness is not known in this age group.

Other medicines and Ambrisentan Mylan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Your doctor may need to adjust your dose of Ambrisentan Mylan if you start taking cyclosporine A (a medicine used after transplant or to treat psoriasis).

If you’re taking rifampicin (an antibiotic used to treat serious infections) your doctor will monitor you when you first start taking Ambrisentan Mylan.

If you’re taking other medicines used to treat PAH (e.g. iloprost, epoprostenol, sildenafil) your doctor may need to monitor you.

^ Tell your doctor or pharmacist if you are taking any of these medicines.

Pregnancy

Ambrisentan Mylan may harm unborn babies conceived before, during or soon after treatment.

^ If it is possible you could become pregnant, use a reliable form of birth control (contraception) while you’re taking Ambrisentan Mylan. Talk to your doctor about this.

^ Don’t take Ambrisentan Mylan if you are pregnant or planning to become pregnant.

^ If you become pregnant or think that you may be pregnant while you’re taking Ambrisentan Mylan, see your doctor immediately.

If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test before you start taking Ambrisentan Mylan and regularly while you are taking this medicine.

Breast-feeding

It is not known if Ambrisentan Mylan is transferred to breast milk.

^ Don’t breast-feed while you’re taking Ambrisentan Mylan. Talk to your doctor about this.

Fertility

If you are a man taking Ambrisentan Mylan, it is possible that this medicine may lower your sperm count. Talk to your doctor if you have any questions or concerns about this.

Driving and using machines

Ambrisentan Mylan may cause side effects, such as low blood pressure, dizziness, tiredness (see section 4), that may affect your ability to drive or use machines. The symptoms of your condition can also make you less fit to drive or use machines.

^ Don’t drive or use machines if you’re feeling unwell.

Ambrisentan Mylan tablets contains lactose and Allura red (E129) Ambrisentan Mylan tablets contain small amounts of a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars:

^ Contact your doctor before taking this medicinal product.

Ambrisentan Mylan tablets contain a colouring agent called Allura red AC Aluminium Lake (E129) which may cause allergic reactions.

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

3. how to take ambrisentan mylan

Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. 2415340

[ Page # 1 of 2 ]

M Mylan


PEPA+


Date/Time of Creation


22/03/21 12:49


Track-Wise PR No.


2415340


Vendor Job No.


597564


Affiliate New Code


2415340


Artwork Proof No.


Aft. Superseded Code


2333841


Pharma Code


NA


Barcode Information


NA


Product Render ID No.


NA


MA Number


EU/1/19/1368/001–004


Main Font Type-1


Helvetica Neue LT Pro


SAP or SPC Code


400551732, 400552733


Main Font Type-2


NA


Packaging Site


Mylan Laboratories Ltd ( Nashik IN)


Min. Font Size


9 pt


Mfg. Lie. No./Code No.


NA


Update in Labeling


Reason for

Revision/Issuance


NA


NA


New Component


Immediately (Stock of supperseded component to be destroyed, if applicable)


After Consumption of Existing (supperseded) stock

Others (specify)

Artwork Implementation Schedule, (■/) whichever is applicable

18.03.2021 – KLD SHARED

Date / Remarks

Date / Remarks


Date of Final

dd / mm / yy

Date of Issue

dd / mm / yy

count mm

Client Market

United Kingdom

Software/Ver. No.

Adobe InDesign CC 9.0

Product Description

LIT. (BF) AMBRISENTAN MYLAN TABS (COMMON) GB V2

New Material Code

75079109

Actual A/w Size

Open Size – 140 × 440 mm

nF Barcode

Other Sizes (if any)

Folded size – 140 × 40 mm

Superseded Code

75077926

Pitch After Every

NA

Component Type

Printed Literature

Eye/Sensor Mark

NA

No. of Printed Colors

1

ITF Barcode Size

NA

Printed Colors CMYK/ PMS Coated/ PMS Color Bridge Coated

black 100%

Non Printed Colors

Die Line

Equivalent with CMYK (Pantones Ref. Code)

NA

Material of Construction

40 gsm ITC Tribeni Paper

Supply Leaflet in Folded Form as Proposed Size

Prepared By

Checked By

Approved By

Packaging Teel

hnical Services

Production

Regulatory Affairs

Quality Assurance



How much Ambrisentan Mylan to take The usual dose of Ambrisentan Mylan is one 5 mg tablet, once a day. Your doctor may decide to increase your dose to 10 mg, once a day.

If you take cyclosporine A, do not take more than one 5 mg tablet of Ambrisentan Mylan once a day.

How to take Ambrisentan Mylan

It is best to take your tablet at the same time each day. Swallow the tablet whole, with a glass of water, do not split, crush or chew the tablet. You can take Ambrisentan Mylan with or without food.

If you take more Ambrisentan Mylan than you should

If you take too many tablets you may be more likely to have side effects, such as headache, flushing, dizziness, nausea (feeling sick), or low blood pressure that could cause light-headedness:

^ Ask your doctor or pharmacist for advice if you take more tablets than prescribed.

If you forget to take Ambrisentan Mylan

If you forget a dose of Ambrisentan Mylan, just take the tablet as soon as you remember, then carry on as before.

^ Don’t take two doses at the same time to make up for a forgotten dose

Don’t stop taking Ambrisentan Mylan without your doctor’s advice

Ambrisentan Mylan is a treatment that you will need to keep on taking to control your PAH.

^ Don’t stop taking Ambrisentan Mylan unless you have agreed this with your doctor.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Conditions you and your doctor need to look out for:

Allergic reactions

This is a common side effect that may affect up to one in 10 people. You may notice a rash or itching and swelling (usually of the face, lips, tongue or throat), which may cause difficulty in breathing or swallowing.

Swelling (oedema), especially of the ankles and feet

This is a very common side effect that may affect more than one in 10 people.

Heart failure

This is due to the heart not pumping out enough blood, causing shortness of breath, extreme tiredness and swelling in the ankles and legs. This is a common side effect that may affect up to one in 10 people.

Anaemia (reduced number of red blood cells)

This is a blood disorder which can cause tiredness, weakness, shortness of breath, and generally feeling unwell. Sometimes this requires a blood transfusion. This is a very common side effect that may affect more than one in 10 people

Hypotension (low blood pressure)

This can cause light-headedness. This is a common side effect that may affect up to one in 10 people.

^ Tell your doctor straight away if you get these effects or if they happen suddenly after taking Ambrisentan Mylan.

It is important to have regular blood tests, to check for anaemia and that your liver is working properly. Make sure that you have also read the information in section 2 under ‘You will need regular blood tests’ and ‘Signs that your liver may not be working properly’.

Other side effects include

Very common side effects:

  • headache
  • dizziness
  • palpitations (fast or irregular heart-beats)
  • worsening shortness of breath shortly after starting Ambrisentan Mylan
  • a runny or blocked nose, congestion or pain in the sinuses
  • feeling sick (nausea)
  • diarrhoea
  • feeling tired

In combination with tadalafil (another PAH medicine) in addition to the above:

  • flushing (redness of the skin)
  • being sick (vomiting)
  • chest pain/discomfort.
  • blurry or other changes to vision
  • fainting
  • abnormal blood test results for liver function
  • a runny nose
  • constipation
  • pain in your stomach (abdomen)
  • chest pain or discomfort
  • flushing (redness of the skin)
  • being sick (vomiting)
  • feeling weak
  • nose bleed
  • rash
In combination with tadalafil

In addition to the above, except abnormal blood test results for liver function:

  • ringing in the ears (tinnitus) only when taking the combination treatment.
  • liver injury
  • inflammation of the liver caused by the body’s own defences (autoimmune hepatitis)
  • sudden hearing loss.

5. how to store ambrisentan mylan

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP.

The expiry date refers to the last day of that month.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. contents of the pack and other information

What Ambrisentan Mylan contains The active substance is ambrisentan.

Each film-coated tablet contains 5 mg or 10 mg.

The other ingredients are lactose, see section 2, ‘Ambrisentan Mylan contains lactose’, microcrystalline cellulose (E460i), sodium croscarmellose, magnesium stearate (E570), polyvinyl alcohol part hydrolysed, titanium dioxide (E171), macrogol/PEG, talc (E553b), Allura red (E129), see section 2 ‘Ambrisentan Mylan contains Allura red (E129)’, Indigo carmine (E132)

What Ambrisentan Mylan looks like and contents of the pack

Ambrisentan Mylan 5 mg film-coated tablet (tablet) is a pink round biconvex tablet engraved with ‘M’ on one side and ‘AN’ on the other side.

Ambrisentan Mylan 10 mg film-coated tablet (tablet) is a pink, capsule shaped tablet engraved with ‘M’ on one side of the tablet and ‘AN1’ on the other side.

Ambrisentan Mylan is supplied as 5 mg and 10 mg film-coated tablets in packs of 30 tablets and unit dose blister packs of 30×1 tablets or 60 x1 tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

Mylan S.A.S.

117 Allee des Parcs

69800 Saint-Priest

France

Manufacturer

Mylan Hungary Kft, Mylan utca 1, 2900 Komarom, Hungary

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom (Northern Ireland) Mylan IRE Healthcare Limited

Tel: +353 18711600

This leaflet was last revised in December 2020

Detailed information on this medicine is available on the European

Medicines Agency web site:.

■ Mylan

2415340

75079109

[ Page # 2 of 2 ]

M Mylan


PEPA+


Date/Time of Creation


22/03/21 12:49


Track-Wise PR No.


2415340


Vendor Job No.


597564


Affiliate New Code


2415340


Artwork Proof No.


Aft. Superseded Code


2333841


Pharma Code


NA


Barcode Information


NA


Product Render ID No.


NA


MA Number


EU/1/19/1368/001–004


Main Font Type-1


Helvetica Neue LT Pro


SAP or SPC Code


400551732, 400552733


Main Font Type-2


NA


Packaging Site


Mylan Laboratories Ltd ( Nashik IN)


Min. Font Size


9 pt


Mfg. Lie. No./Code No.


NA


Update in Labeling


Reason for

Revision/Issuance


NA


NA


New Component


Immediately (Stock of supperseded component to be destroyed, if applicable)


After Consumption of Existing (supperseded) stock

Others (specify)

Artwork Implementation Schedule, (■/) whichever is applicable


Date of Final

dd / mm / yy

Date of Issue

dd / mm / yy

BUS

Count Bam

Client Market

United Kingdom

Software/Ver. No.

Adobe InDesign CC 9.0

Product Description

LIT. (BF) AMBRISENTAN MYLAN TABS (COMMON) GB V2

New Material Code

75079109

Actual A/w Size

Open Size – 140 × 440 mm

nF Barcode

Other Sizes (if any)

Folded size – 140 × 40 mm

Superseded Code

75077926

Pitch After Every

NA

Component Type

Printed Literature

Eye/Sensor Mark

NA

No. of Printed Colors

1

ITF Barcode Size

NA

Printed Colors CMYK/ PMS Coated/ PMS Color Bridge Coated

black 100%

Non Printed Colors

Die Line

Equivalent with CMYK (Pantones Ref. Code)

NA

Material of Construction

40 gsm ITC Tribeni Paper

Supply Leaflet in Folded Form as Proposed Size

Prepared By

Checked By

Approved By

Packaging Teel

hnical Services

Production

Regulatory Affairs

Quality Assurance


18.03.2021 – KLD SHARED

Date / Remarks

Date / Remarks

Revision

History

SOP-000565164-FORM-000638313-A07–02–01–20